

Lidia Oostvogels

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7802292/publications.pdf>

Version: 2024-02-01

15
papers

1,331
citations

759233

12
h-index

996975

15
g-index

15
all docs

15
docs citations

15
times ranked

1584
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. <i>New England Journal of Medicine</i> , 2016, 375, 1019-1032.	27.0	752
2	Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 123.	7.4	143
3	Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 988-1000.	9.1	136
4	Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention. <i>Expert Review of Vaccines</i> , 2018, 17, 619-634.	4.4	77
5	Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1231-1238.	3.6	36
6	Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials. <i>Vaccine</i> , 2019, 37, 2482-2493.	3.8	34
7	Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial. <i>BMC Infectious Diseases</i> , 2013, 13, 348.	2.9	32
8	Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals. <i>Journal of the American Geriatrics Society</i> , 2021, 69, 744-752.	2.6	30
9	Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2865-2872.	3.3	22
10	The Impact of Reactogenicity After the First Dose of Recombinant Zoster Vaccine on the Physical Functioning and Quality of Life of Older Adults: An Open-Label, Phase III Trial. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 1217-1224.	3.6	20
11	Adjuvanted recombinant zoster vaccine in adult autologous stem cell transplant recipients: polyfunctional immune responses and lessons for clinical practice. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4144-4154.	3.3	16
12	Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2628-2633.	3.3	13
13	Evaluation of two frailty indices, with practical application in a vaccine clinical trial. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2960-2968.	3.3	9
14	Impact of Reactogenicity After Two Doses of Recombinant Zoster Vaccine Upon Physical Functioning and Quality of Life: An Open Phase III Trial in Older Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2021, 76, 485-490.	3.6	7
15	149. Immunogenicity, Safety, and Post-hoc Efficacy Assessment of the Adjuvanted Recombinant Zoster Vaccine in Adults with Hematologic Malignancies: A Phase 3, Randomized Clinical Trial. <i>Open Forum Infectious Diseases</i> , 2018, 5, S9-S10.	0.9	4